Overview
Product name | Recombinant Human TNFSF7/CD27 Ligand/CD70 Protein |
---|
Catalog No. | RP01720 |
---|
Description | Recombinant Human TNFSF7/CD27 Ligand/CD70 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln39-Pro193) of human CD70/TNFSF7/CD27 Ligand (Accession #NP_001243.1) fused with and a 6×His tag at the N-terminus. |
---|
Bio-Activity | Measured by its binding ability in a functional ELISA.Immobilized Human TNFSF7 (Catalog: RP01720) at 2 μg/mL (100 μL/well) can bind Human TNFRSF7 (Catalog: RP01358) with a linear range of 0.2-82 ng/mL.
|
---|
Purity | > 97% by SDS-PAGE. |
---|
Endotoxin | <1EU/μg |
---|
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
---|
Species | Human |
---|
Calculated MW | 17.98 kDa |
---|
Background
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.
Product information
Synonym | CD27L; LPFS3; CD27-L; CD27LG; TNFSF7; TNLG8A; CD70 |
---|
Expression Host | HEK293 cells |
---|
Tag | N-6His |
---|
Swiss-Prot | |
---|
Gene ID | |
---|
Usage guide
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
---|
* For research use only. Not for therapeutic or diagnostic purposes.